Biocept Inc (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall tells Proactive it has formed a collaboration with Quest Diagnostics Inc (NYSE:DGX) (FRA:QDI) to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel.
With a physician order, Nall says that patients will be able to provide a blood specimen for testing at one of Quest’s 2,200 patient service centers across the US. Nall also updated on its coronavirus testing services, as well as an update on CNSide.